Eyenovia (Eyenovia) Days Payable : 48,347.29 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Eyenovia Days Payable?

Eyenovia's average Accounts Payable for the three months ended in Dec. 2023 was $1.59 Mil. Eyenovia's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil. Hence, Eyenovia's Days Payable for the three months ended in Dec. 2023 was 48,347.29.

The historical rank and industry rank for Eyenovia's Days Payable or its related term are showing as below:

EYEN' s Days Payable Range Over the Past 10 Years
Min: 350.86 Med: 685.06 Max: 145133.13
Current: 133626.5

During the past 9 years, Eyenovia's highest Days Payable was 145133.13. The lowest was 350.86. And the median was 685.06.

EYEN's Days Payable is ranked better than
99.03% of 720 companies
in the Biotechnology industry
Industry Median: 147.17 vs EYEN: 133626.50

Eyenovia's Days Payable increased from Dec. 2022 (0.00) to Dec. 2023 (48,347.29). It may suggest that Eyenovia delayed paying its suppliers.

Eyenovia Days Payable Historical Data

The historical data trend for Eyenovia's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eyenovia Days Payable Chart

Eyenovia Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

685.06

350.86

145,133.13

Eyenovia Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															-	-	-	124,966.88	48,347.29

Competitive Comparison of Eyenovia's Days Payable

For the Biotechnology subindustry, Eyenovia's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eyenovia's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eyenovia's Days Payable distribution charts can be found below:

* The bar in red indicates where Eyenovia's Days Payable falls into.

Eyenovia Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Eyenovia's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (1.428	+	1.753)	/	2 )	/	0.004	*	365
=	1.5905					/	0.004	*	365
=	145,133.13

Eyenovia's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (1.426	+	1.753)	/	2 )	/	0.003	*	365 / 4
=	1.5895					/	0.003	*	365 / 4
=	48,347.29

Eyenovia Days Payable Related Terms

Thank you for viewing the detailed overview of Eyenovia's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Eyenovia (Eyenovia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eyenovia Inc (NAS:EYEN) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

295 Madison Avenue, Suite 2400, New York, NY, USA, 10017

Website

https://www.eyenovia.com

Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

Executives

Michael M Rowe	director, officer: Chief Executive Officer	C/O EYENOVIA, INC., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Ellen R Strahlman	director	ALTRIA GROUP, INC., 6601 W. BROAD STREET, RICHMOND VA 23230
Stuart M. Grant	10 percent owner	11 SUMMIT LANE, GREENVILLE DE 19807
Ram Palanki	director	C/O EYENOVIA, INC, 295 MADISON AVENUE SUITE 2400, NEW YORK NY 10017
Rachel Jacobson	director	C/O EYENOVIA INC, 295 MADISON AVENUE SUITE 2400, NEW YORK NY 10017
John P Gandolfo	officer: Chief Financial Officer	62 TERRACE ROAD, WAYNE NJ 07470
Bren Kern	officer: Chief Operating Officer	295 MADISON AVENUE, SUITE 2400, C/O EYENOVIA, INC., NEW YORK NY 10017
Mather Charles E Iv	director	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Tsontcho Ianchulev	director	501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Stephen Keith Benjamin	director	135 NORTH CHURCH STREET, SPARTANBURG SC 29306
Julia A Haller	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Lee Kenneth B Jr	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
Curt H Labelle	director	C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011
Anthony Y Sun	director	C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10106
Fredric N Eshelman	director	PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401